Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1-based Therapy Discontinuation

Inclusion Criteria: 1. Age 18-80 years at screening 2. History of BMI ≥30 kg/m² 3. Current or recent (within 8 weeks) treatment with injectable semaglutide, tirzepatide, or similar GLP-1 based medication 4. Achieved ≥10% body weight loss since initiation of injectable semaglutide, tirzepatide or similar GLP-1 based medication 5. Willing to participate in the study after reviewing study infographic and confirming understanding of randomization and study procedures 6. Ability to understand and the willingness to sign a written informed consent document 7. Residence in Massachusetts Exclusion C…